Discovery on How Glioblastoma Cells Disrupt Brain's Barrier Leads to Potential Therapies
the Cancer Therapy Advisor take:
Glioblastoma is an aggressive, devastating type of brain tumor that spreads rapidly. According to a mice study published in Nature Communications, researchers found that during the early stages of glioblastoma progression that glioblastoma cells took over cerebral blood vessels, which damaged the blood-brain barrier (BBB).
The BBB protects the brain from harmful materials threatening to leak inside of it, and the BBB also regulates the transportation of important molecules between the blood and the brain. Parts of the BBB are tight junctions that make seals between blood vessels’ endothelial cells. A specialized brain cell, known as an astrocyte, has extensive projections called endfeet and covers blood vessels. The endfeet regulate the brain’s blood flow by releasing chemicals that make blood vessels contract or expand.
Harald Sontheimer, PhD, and his colleagues studied glioblastoma cells, astrocytes, and cerebral blood vessels and how they interact with each other. The researchers found that a majority of the glioblastoma cells outside of the tumor resided between the endfeet and the blood vessel’s outer surface. The glioblastoma cells migrated along blood vessels, took the blood’s nutrients, and hijacked the astrocytes’ control over blood flow, which caused the BBB’s breakdown.
These findings could lead to new treatments using anti-invasive agents for glioblastoma.
Discovery on How Glioblastoma Cells Disrupt Brain’s Barrier Leads to Potential Therapies
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin on Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer